<?xml version="1.0" encoding="UTF-8"?>
<p id="Par27">In April 2014, the WHO published the first guidelines on HCV, which note how HCV infection takes a different path than other chronic viral infections (including human immunodeficiency virus (HIV) infection) because the treatments currently available allow eradication. The guidelines are divided into nine recommendations, which include various aspects: the indication to increase the number of people subject to screening, suggestions on how to reduce damage to the liver and which treatments to use for different cases, according to the drugs approved up to December 2013 [
 <xref ref-type="bibr" rid="CR20">20</xref>]. These guidelines were then updated in 2016 and 2018 because other new drugs had been approved in the meantime [
 <xref ref-type="bibr" rid="CR21">21</xref>]. The WHO’s follow-up resolution called on the Member States to develop and put into practice a national programme based on epidemiological data. The new WHO strategy [
 <xref ref-type="bibr" rid="CR22">22</xref>] introduces global goals against viral hepatitis. This includes a 30% reduction in new cases of hepatitis B virus (HBV) and HCV infections and a 10% reduction in mortality by 2020.
</p>
